Metabolic profiling identifies lung tumor responsiveness to erlotinib.
Metabolic profiling identifies lung tumor responsiveness to erlotinib.
复制标题
DOI：
10.1016/j.yexmp.2009.04.004
复制
发表时间：
2009-08
影响因子：
3.6
通讯作者：
Miller, Donald M.
中科院分区：
文献类型：
--
作者：
Fan, Teresa W. -M.;Lane, Andrew N.;Higashi, Richard M.;Bousamra, Michael, II;Kloecker, Goetz;Miller, Donald M.
A subtype of non-small cell lung cancer, bronchioalveolar adenocarcinoma (BAC), is more prevalent in Asian female non-smokers, and is more likely to respond to treatment with tyrosine kinase inhibitors such as erlotinib and gefitinib. Nuclear magnetic resonance and mass spectrometry-based metabolomic analysis of extracts from two different lung lesions and surrounding non-cancerous tissues of a BAC patient showed novel protein and phospholipid-associated metabolic differences that correlated with tumor development as well as PET and erlotinib sensitivity.
登录
查看更多内容
影响因子：
45.3
作者：
Wakelee, Heather A.;Chang, Ellen T.;West, Dee W.
通讯作者：
West, Dee W.
影响因子：
3.5
作者：
Sakuma, Yuji;Matsukuma, Shoichi;Miyagi, Yohei
通讯作者：
Miyagi, Yohei
影响因子：
11.5
作者：
Giaccone, Giuseppe;Ruiz, Marielle Gallegos;Soria, Jean-Charles
通讯作者：
Soria, Jean-Charles
影响因子：
20.4
作者：
Kris, Mark G.;Giaccone, Giuseppe;West, Howard
通讯作者：
West, Howard
影响因子：
5.3
作者：
Na, Im Il;Rho, Jin Kyung;Lee, Jae Cheol
通讯作者：
Lee, Jae Cheol